Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - HYPERION THERAPEUTICS INC | d492969d8k.htm |
Exhibit 99.1
Contact:
Shari Annes, Investor Relations
650-888-0902
sannes@annesassociates.com
Hyperion Therapeutics Announces Fourth Quarter and Full Year 2012
Operating Results
South San Francisco, CA – February 25, 2013 – Hyperion Therapeutics, Inc. (Nasdaq GM: HPTX) today reported financial operating results for the fourth quarter and the year ended December 31, 2012.
According to Chief Executive Officer, Donald J. Santel, “Since the FDA’s approval of RAVICTI™ (glycerol phenylbutyrate) on February 1st, we have been singularly focused on our commercial roll-out and expect to have product available for launch by the end of April. Specifically, we have begun the training of our sales and market access field teams and have initiated reimbursement dialogues with key private and public payers. We also expect to begin the final due diligence review related to our option to purchase BUPHENYL® (sodium phenylbutyrate) Tablets and Powder and AMMONUL® (sodium phenylacetate and sodium benzoate) injection 10%/10% from Valeant in the near future.”
Fourth Quarter and Full Year 2012 Financial Results
Hyperion reported net losses of $8.3 million and $32.3 million for the fourth quarter and year ended December 31, 2012, respectively, compared with net losses of $8.7 million and $29.4 million for the same periods of 2011.
Research and development expenses for the fourth quarter 2012 were $3.0 million compared with $3.5 million for the same period in 2011. For the full year 2012, research and development expenses were $17.1 million compared with $17.2 million for the full year 2011. The decrease for both the fourth quarter and full year for research and development expenses was primarily due to reduced clinical development and
consulting expenses related to the company’s HE Phase II trial and the long-term safety extension trial in adults with UCD both of which were largely completed in 2011. These decreases were partially offset by increases in 2012 in manufacturing related expenses, which were expensed to research and development as RAVICTI was not yet approved as well as the $5.7 million in expenses incurred in connection with the purchase of RAVICTI.
General and administrative expenses for the fourth quarter 2012 were $2.5 million compared to $3.1 million for the same period of 2011. For the full year 2012, general and administrative expenses decreased to $7.5 million compared to $8.2 million for the full year 2011. The decrease in the fourth quarter compared to the same period last year was primarily due to the decrease in certain non-recurring legal costs incurred in 2011. The decrease for the full year 2012 was primarily due to the decrease in these legal costs partially offset by increases in compensation-related, consulting and insurance expenses.
Selling and marketing expenses for the fourth quarter 2012 were $2.3 million, compared to $0.1 million for the same period of 2011. For the full year 2012, selling and marketing expenses were $4.0 million compared to $0.8 million for the same period of 2011. The increase for both the fourth quarter and the full year was primarily due to increases in compensation-related expenses related to new hires as well as consulting fees as the company strategically expanded its commercial infrastructure in preparation for the commercialization of Ravicti in UCD.
As of December 31, 2012, Hyperion had cash and cash equivalents of $49.9 million.
About Hyperion Therapeutics
Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. For more information, please visit www.hyperiontx.com
Forward-Looking Statements:
To the extent that statements contained in this press release are not descriptions of historical facts regarding Hyperion, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our expectations regarding the timing of any commercial launch of Ravicti. Forward-looking statements in this release involve substantial risks and uncertainties that could cause future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks related to: the uncertain clinical development process; that the U.S. Food and Drug Administration may not be satisfied with preclinical data, including carcinogenicity data; or the success and timing of commercialization efforts; the fact that the patient population suffering from UCD is small and has not been established with precision; the ability to obtain adequate clinical supplies of Ravicti; and the ability to raise sufficient capital to complete the development of and commercialize Ravicti in UCD. Hyperion undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see the section entitled “Risk Factors” in Hyperion’s Annual Report on Form 10-K for the year ended December 31, 2012, and in subsequent filings with the Securities and Exchange Commission.
Hyperion Therapeutics, Inc.
Consolidated Statements of Operations
(In thousands, except share and per share amounts)
| Three Months
Ended December 31, (Unaudited) |
Twelve Months
Ended December 31,(1) |
|||||||||||||||
| 2012 | 2011 | 2012 | 2011 | |||||||||||||
| Operating expenses |
||||||||||||||||
| Research and development |
$ | 3,033 | $ | 3,544 | $ | 17,046 | $ | 17,236 | ||||||||
| General and administrative |
2,450 | 3,058 | 7,530 | 8,162 | ||||||||||||
| Selling and marketing |
2,312 | 132 | 3,957 | 761 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
7,795 | 6,734 | 28,533 | 26,159 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from operations |
(7,795 | ) | (6,734 | ) | (28,533 | ) | (26,159 | ) | ||||||||
| Interest income |
1 | 9 | 12 | 28 | ||||||||||||
| Interest expense |
(491 | ) | (867 | ) | (3,703 | ) | (2,554 | ) | ||||||||
| Other income (expense), net |
— | (1,062 | ) | (39 | ) | (731 | ) | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss attributable to common stockholders |
$ | (8,285 | ) | $ | (8,654 | ) | $ | (32,263 | ) | $ | (29,416 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share attributable to common stockholders: |
||||||||||||||||
| Basic and diluted |
$ | (0.50 | ) | $ | (18.44 | ) | $ | (4.45 | ) | $ | (62.68 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average number of shares used to compute net loss per share of common stock: |
||||||||||||||||
| Basic and diluted |
16,613,320 | 469,319 | 7,256,537 | 469,319 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| (1) | Derived from the audited financial statements, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. |
Hyperion Therapeutics, Inc.
Consolidated Balance Sheets
(In thousands)
| December 31, 2012 (1) |
December 31, 2011 (1) |
|||||||
| Assets |
||||||||
| Current assets |
||||||||
| Cash and cash equivalents |
$ | 49,853 | $ | 7,018 | ||||
| Prepaid expenses and other current assets |
1,155 | 741 | ||||||
| Restricted cash |
— | 305 | ||||||
|
|
|
|
|
|||||
| Total current assets |
51,008 | 8,064 | ||||||
| Property and equipment, net |
49 | 19 | ||||||
| Restricted cash |
— | 25 | ||||||
| Other non-current assets |
147 | 34 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 51,204 | $ | 8,142 | ||||
|
|
|
|
|
|||||
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit) |
||||||||
| Current liabilities |
||||||||
| Accounts payable |
$ | 2,177 | $ | 1,887 | ||||
| Accrued liabilities |
2,540 | 3,310 | ||||||
| Call option liability |
— | 737 | ||||||
| Convertible notes payable |
— | 23,412 | ||||||
| Notes payable, current portion |
4,348 | — | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
9,065 | 29,346 | ||||||
| Warrants liability |
— | 2,574 | ||||||
| Notes payable, net of current portion |
7,750 | — | ||||||
|
|
|
|
|
|||||
| Total liabilities |
16,815 | 31,920 | ||||||
|
|
|
|
|
|||||
| Convertible preferred stock |
— | 58,326 | ||||||
|
|
|
|
|
|||||
| Stockholders’ equity (deficit) |
||||||||
| Preferred stock |
— | — | ||||||
| Common stock |
2 | — | ||||||
| Additional paid-in capital |
173,384 | 24,630 | ||||||
| Deficit accumulated during the development stage |
(138,997 | ) | (106,734 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity (deficit) |
34,389 | (82,104 | ) | |||||
|
|
|
|
|
|||||
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) |
$ | 51,204 | $ | 8,142 | ||||
|
|
|
|
|
|||||
| (1) | Derived from the audited financial statements, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. |
###